The Needle Biopsy Market is projected to reach US$ 2.45 Billion by 2031, registering a CAGR of 6.5% during 2025–2031. The market is expanding as healthcare providers increasingly rely on minimally invasive tissue sampling techniques to support the diagnosis and evaluation of cancer and other diseases. Growth is supported by the rising burden of cancer, increasing adoption of image-guided procedures, and continued advances in biopsy needle design and procedural technologies.
Needle biopsy involves obtaining tissue or fluid samples using specialized needles for pathological and diagnostic evaluation. Compared with more invasive surgical biopsy approaches, needle-based techniques can offer smaller incisions, shorter procedures, and reduced patient discomfort in appropriate clinical settings. Improvements in imaging technologies and biopsy devices are further supporting their use across hospitals, diagnostic centers, and specialized healthcare facilities.
What is driving the market?
The increasing incidence of cancer and growing demand for minimally invasive diagnostic procedures are major factors supporting market growth. Needle biopsy is widely used to obtain tissue samples from suspicious lesions and masses, supporting pathological assessment and treatment planning. As cancer screening and diagnostic programs expand, demand for reliable tissue sampling technologies is also increasing.
The growing adoption of image-guided biopsy procedures is another important growth factor. Ultrasound, computed tomography, mammography, and other imaging modalities can help clinicians accurately target suspicious areas and guide needle placement. Improved imaging and navigation capabilities can support procedural precision and expand the use of needle biopsy across different anatomical sites.
Technological advancements are also influencing market development. Manufacturers are developing biopsy needles and associated devices with improvements in sampling performance, handling, precision, and compatibility with image-guided procedures. These developments are providing healthcare professionals with additional options for obtaining adequate tissue samples while supporting efficient diagnostic workflows.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00004747
Which region leads?
North America represents an important market for needle biopsy, supported by advanced healthcare infrastructure, established cancer diagnostic services, and widespread adoption of minimally invasive procedures. The region also benefits from the presence of major medical device manufacturers and increasing utilization of image-guided diagnostic technologies.
Europe is another significant market, supported by established healthcare systems, cancer screening initiatives, and growing adoption of minimally invasive diagnostic procedures. Improvements in imaging technologies and increasing demand for early and accurate disease diagnosis are contributing to regional opportunities.
The Asia Pacific region presents considerable growth potential as healthcare infrastructure expands and access to advanced diagnostic services improves. Rising healthcare expenditure, increasing cancer awareness, and growing availability of imaging and pathology services are supporting demand for needle biopsy technologies.
Latin America and the Middle East & Africa are also witnessing gradual improvements in diagnostic infrastructure. Expansion of healthcare facilities, increasing access to specialized diagnostic services, and greater awareness of early disease detection may support future market development.
Which segment leads?
Needle biopsy procedures used for cancer diagnosis and lesion evaluation represent an important area of demand, reflecting the growing need for tissue confirmation during diagnostic workups. Needle biopsy technologies can be used across a range of clinical applications, with procedure selection depending on the location and characteristics of the lesion, patient condition, imaging guidance, and physician preference.
Core needle biopsy and fine-needle aspiration represent established approaches within the broader needle biopsy field. Core needle techniques can provide tissue architecture for pathological evaluation, while fine-needle aspiration can obtain cellular material for diagnostic assessment. Continued improvements in needle design and sampling technology are supporting their use across different clinical applications.
Hospitals, diagnostic centers, specialty clinics, and other healthcare facilities represent important end users. The expansion of diagnostic imaging services and specialized oncology centers is creating additional opportunities for manufacturers of biopsy needles and associated devices.
Which companies are prominent?
The competitive landscape includes medical device and healthcare technology companies developing and commercializing biopsy needles, tissue sampling devices, and related diagnostic technologies. Prominent companies include Boston Scientific Corporation, Cook Medical, CareFusion Corporation, Hologic, Inc., Medax, C. R. Bard, Inc., Moller Medical GmbH, BD, Hakko Co., Ltd., and Argon Medical Devices, Inc.
These companies compete through product innovation, biopsy needle design, sampling performance, image-guided procedure compatibility, manufacturing capabilities, and geographic expansion. Strategic differentiation increasingly depends on device precision, ease of use, procedural efficiency, and integration with modern diagnostic workflows. The list reflects prominent market participants rather than a revenue-ranked market-share table.
What is changing in 2026?
The market is shifting toward more precise, image-guided, and minimally invasive tissue sampling procedures. Healthcare providers are increasingly using advanced imaging technologies to identify and target suspicious lesions, supporting accurate needle placement and potentially improving the quality of tissue samples.
Another important trend is the development of biopsy devices designed to improve sampling efficiency and procedural control. Manufacturers are focusing on needle geometry, tissue acquisition, handling characteristics, and compatibility with different imaging modalities to address varying clinical requirements.
The integration of biopsy procedures with advanced diagnostic workflows is also gaining importance. Tissue samples obtained through needle biopsy can support histopathological and molecular evaluation, helping healthcare teams characterize diseases and inform subsequent treatment decisions where clinically appropriate.
At the same time, healthcare providers are placing greater emphasis on early diagnosis, procedural safety, patient comfort, and efficient diagnostic pathways. These priorities are influencing the adoption and development of needle biopsy technologies across hospitals and specialized diagnostic facilities.
Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPRE00004747
What are the major investment opportunities?
Major investment opportunities are emerging across advanced biopsy devices, image-guided procedures, oncology diagnostics, and minimally invasive tissue sampling technologies. Companies investing in improved needle designs and sampling technologies can address the growing demand for efficient and precise tissue acquisition.
Image-guided biopsy represents another opportunity as diagnostic centers and hospitals expand their imaging capabilities. Technologies that support accurate targeting, procedural control, and compatibility with ultrasound, computed tomography, mammography, and other imaging modalities can provide opportunities for product portfolio expansion.
The increasing use of tissue samples for advanced pathological and molecular assessment also creates opportunities for companies operating at the intersection of biopsy and precision diagnostics. Improvements in tissue acquisition can support downstream diagnostic workflows and facilitate more detailed disease characterization.
Emerging markets offer additional expansion potential as healthcare infrastructure, cancer screening, diagnostic imaging, and specialized oncology services improve. Manufacturers can pursue strategic partnerships, distribution networks, and local market expansion while focusing on product quality, regulatory requirements, clinical utility, and cost-effective diagnostic solutions.
Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish
Related Reports:
Livestock Monitoring System Market Trends, Size & Forecast by 2034
In-Vitro Diagnostic Instruments Market Demand, Trends & Forecast by 2034
About Us
The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.
Contact US
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
E-mail : sales@theinsightpartners.com
